$PBM News

Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met

Psyence Biomedical Completes Its Additional Investment In PsyLabs Of $2,599,896

Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine

Psyence Biomedical Signs Manufacturing Services Agreement With DEA-Registered Benuvia For Planned U.S. Manufacture Of Pharmaceutical-Grade Ibogaine Active Pharmaceutical Ingredient

Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation

Psyence Biomedical Unit TIRC Signs Binding Term Sheet With Psyence Labs For An Exclusive License, Supply And Wholesale Distribution Arrangement For Psylabs’ Pharmaceutical-Grade Ibogaine In The U.S.

Psyence BioMed Announces Strategic Ibogaine Investment

Psyence Biomedical Agrees To Make Cash Investment Of Up To $5M In Psyence Labs

Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development

Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Psyence BioMed Establishes Active Ibogaine Operations, Production Capabilities In Africa

Prestige Consumer Healthcare Announces agreement To Acquire LaCorium Health, A Leader In Australian Therapeutic Skin Care For ~150M

FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Psyence Biomedical Announces First Patient Dosed In Phase Iib Clinical Trial Evaluating NPX-5 For Treatment Of Adjustment Disorder In Patients With Cancer In Palliative Care Setting

Psyence Biomedical Announces First Patient Dosed In Phase Iib Clinical Trial Evaluating NPX-5 For Treatment Of Adjustment Disorder In Patients With Cancer In Palliative Care Setting

Why Is Psyence Biomedical Stock Falling Wednesday?

Why Is Psyence Biomedical Stock Trading Lower On Tuesday?

Psyence Biomedical shares are trading higher after President Trump signed an executive order on accelerating medical treatments for serious mental illness.